Header Logo

Connection

MARGARET SPITZ to Lymphocytes

Back to Details
This is a "connection" page, showing publications MARGARET SPITZ has written about Lymphocytes.
MARGARET SPITZ
Connection Strength
2.530
Lymphocytes
  1. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis. 2007 Jul; 28(7):1430-6.
    View in: PubMed
    Score: 0.239
  2. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8.
    View in: PubMed
    Score: 0.171
  3. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst. 2000 May 03; 92(9):737-43.
    View in: PubMed
    Score: 0.149
  4. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst. 1998 Sep 16; 90(18):1393-9.
    View in: PubMed
    Score: 0.133
  5. Lung carcinoma patients with a family history of cancer and lymphocyte primary chromosome 9 aberrations. Cancer. 1997 Apr 15; 79(8):1527-32.
    View in: PubMed
    Score: 0.120
  6. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 1996 Sep 15; 56(18):4103-7.
    View in: PubMed
    Score: 0.115
  7. Mutagen sensitivity exhibits a dose-response relationship in case-control studies. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):577-8.
    View in: PubMed
    Score: 0.114
  8. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res. 1995 Feb 01; 55(3):557-61.
    View in: PubMed
    Score: 0.103
  9. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol. 2011 Nov 01; 29(31):4121-8.
    View in: PubMed
    Score: 0.082
  10. Rapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers. BMC Cancer. 2010 Aug 18; 10:439.
    View in: PubMed
    Score: 0.076
  11. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7194-201.
    View in: PubMed
    Score: 0.059
  12. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res. 2006 Jun 15; 66(12):5993-6.
    View in: PubMed
    Score: 0.057
  13. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.052
  14. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Mar; 14(3):748-52.
    View in: PubMed
    Score: 0.052
  15. Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes Cancer. 2004 Dec; 41(4):379-89.
    View in: PubMed
    Score: 0.051
  16. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003 Oct; 42(1):1-8.
    View in: PubMed
    Score: 0.047
  17. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003 Aug 20; 95(16):1211-8.
    View in: PubMed
    Score: 0.047
  18. Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. Mol Carcinog. 2003 Mar; 36(3):123-9.
    View in: PubMed
    Score: 0.045
  19. Assessment of insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk. Methods Mol Med. 2003; 75:279-87.
    View in: PubMed
    Score: 0.045
  20. BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. Cancer. 2002 Aug 01; 95(3):563-8.
    View in: PubMed
    Score: 0.043
  21. In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck. Int J Cancer. 2001 Aug 01; 93(3):436-40.
    View in: PubMed
    Score: 0.040
  22. Cryopreserving whole blood for functional assays using viable lymphocytes in molecular epidemiology studies. Cancer Lett. 2001 May 26; 166(2):155-63.
    View in: PubMed
    Score: 0.040
  23. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000 Nov 01; 92(21):1764-72.
    View in: PubMed
    Score: 0.038
  24. Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo- 2'-deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. Mol Carcinog. 2000 Jan; 27(1):34-46.
    View in: PubMed
    Score: 0.036
  25. Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. Br J Cancer. 1999 May; 80(3-4):453-7.
    View in: PubMed
    Score: 0.035
  26. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer. 1998 Sep 15; 83(6):1118-27.
    View in: PubMed
    Score: 0.033
  27. Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res. 1998 Jul; 4(7):1773-8.
    View in: PubMed
    Score: 0.033
  28. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res. 1998 Apr 15; 58(8):1605-8.
    View in: PubMed
    Score: 0.032
  29. Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis. 1998 Jan; 19(1):93-8.
    View in: PubMed
    Score: 0.032
  30. Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res. 1996 Sep 01; 56(17):3975-9.
    View in: PubMed
    Score: 0.029
  31. Fluorescent in situ hybridization analysis in blood lymphocytes of lung cancer patients. Anticancer Res. 1996 May-Jun; 16(3A):1187-92.
    View in: PubMed
    Score: 0.028
  32. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev. 1996 Mar; 5(3):199-204.
    View in: PubMed
    Score: 0.028
  33. Genetic susceptibility to lung cancer as determined by lymphocytic chromosome analysis. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov; 4(7):743-9.
    View in: PubMed
    Score: 0.027
  34. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev. 1995 Mar; 4(2):99-103.
    View in: PubMed
    Score: 0.026
  35. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr. 1995; (18):29-33.
    View in: PubMed
    Score: 0.026
  36. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect Prev. 1993; 17(6):575-83.
    View in: PubMed
    Score: 0.022
  37. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst. 2008 Aug 06; 100(15):1104-12.
    View in: PubMed
    Score: 0.016
  38. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1517-22.
    View in: PubMed
    Score: 0.015
  39. Irradiation-induced telomerase activity and the risk of lung cancer: a pilot case-control study. Cancer. 2007 Mar 15; 109(6):1157-63.
    View in: PubMed
    Score: 0.015
  40. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer. 2004 Dec; 41(4):330-8.
    View in: PubMed
    Score: 0.013
  41. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec; 134(12):3362-9.
    View in: PubMed
    Score: 0.013
  42. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 2003 Apr 02; 95(7):540-7.
    View in: PubMed
    Score: 0.011
  43. A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. Int J Cancer. 2002 Dec 10; 102(5):536-40.
    View in: PubMed
    Score: 0.011
  44. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res. 2002 Nov 30; 509(1-2):165-74.
    View in: PubMed
    Score: 0.011
  45. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002 Jan 15; 94(2):393-7.
    View in: PubMed
    Score: 0.010
  46. Modification of lung cancer susceptibility by green tea extract as measured by the comet assay. Cancer Detect Prev. 2002; 26(6):411-8.
    View in: PubMed
    Score: 0.010
  47. Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res. 2001 Nov 01; 61(21):7819-24.
    View in: PubMed
    Score: 0.010
  48. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate. 2001 Jun 01; 47(4):269-75.
    View in: PubMed
    Score: 0.010
  49. Comparative efficacy as antioxidants between ascorbic acid and epigallocatechin gallate on cells of two human lymphoblastoid lines. Cancer Genet Cytogenet. 2001 Jan 15; 124(2):169-71.
    View in: PubMed
    Score: 0.010
  50. Gamma-radiation-induced single cell DNA damage as a measure of susceptibility to lung cancer: a preliminary report. Int J Oncol. 2000 Aug; 17(2):399-404.
    View in: PubMed
    Score: 0.009
  51. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis. 2000 Aug; 21(8):1527-30.
    View in: PubMed
    Score: 0.009
  52. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet. 1999 Apr; 110(1):65-9.
    View in: PubMed
    Score: 0.009
  53. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):567-70.
    View in: PubMed
    Score: 0.008
  54. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res. 1996 Aug 15; 56(16):3638-41.
    View in: PubMed
    Score: 0.007
  55. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev. 1996 Aug; 5(8):639-44.
    View in: PubMed
    Score: 0.007
  56. Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev. 1996 Jul; 5(7):527-32.
    View in: PubMed
    Score: 0.007
  57. Glutathione s-transferase genotypes as risk factors for head and neck cancer. Am J Surg. 1995 Nov; 170(5):499-501.
    View in: PubMed
    Score: 0.007
  58. Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr; 2(2):103-6.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.